Navigation Links
CryoLife Announces First Clinical Use of BioFoam(R)
Date:9/10/2009

ding statements regarding hopes that BioFoam will reduce the time required to achieve hemostasis during liver resection surgery and reduce the number of complications following surgery, potential distribution timing and uses and applications for BioFoam and timing of enrollment in the feasibility phase of the Company's BioFoam IDE submission. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. These risks and uncertainties include that BioFoam may not prove safe or effective for its intended uses, that BioFoam may not achieve hemostasis in liver resections or reduce complications following surgery due to any number of factors that we will not be able to identify until further procedures are performed, that BioFoam may not be useful in other future surgical applications, that the Company may not start feasibility phase enrollment in quarter 4 of 2009 due to any number of factors, including unanticipated delays in obtaining FDA and U.S. Department of Defense approval, and that BioFoam development may not result in a commercial product on the time table anticipated, or at all, due to factors beyond our control, including potential lack of acceptance by the medical community. For additional risks impacting the Company's business, see the Risk Factors section of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and the Company's subsequent Form 10-Q filings. The Company does not undertake to update its forward-looking statements.

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com

    Media Contacts:

    D. Ashley Lee
    Executive Vice President, Chief Financial
    Officer and Chief Operating Officer
    Phone:  770-419-3355

    Dana H
'/>"/>
SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. CryoLifes Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World
2. CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
3. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
4. CryoLife Reports Record First Quarter Revenues of $26.7 Million
5. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
6. CryoLife to Present at Sidotis 13th Annual New York Emerging Growth Institutional Forum
7. CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
8. CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results
9. CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone
10. CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference
11. CryoLifes Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... 7, 2015  SME,s Advanced Manufacturing Media is proud ... 30" issue, celebrating young men and women who have ... July issue of Manufacturing Engineering ... for their accomplishments. Among the standouts: Christopher Tyler ... on optimizing the topology of flapping wing vehicles; ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... by 2020 from $107.56 million in 2015, growing at a CAGR of 17.89% ... DNA-based aptamers, RNA-based aptamers, and XNA-based aptamers. Based on applications, the report is ...
(Date:7/7/2015)... ... July 07, 2015 , ... Currently deployed within ... was developed to solve many of the complex logistical and data management challenges ... multiple clinical sites and/or remote data coordination centers. , CentrePoint drastically reduces ...
(Date:7/6/2015)... ... 2015 , ... A study by a multidisciplinary research team, ... adapt through genetic modifications to fight back against the effects of medication designed ... insights may provide clues to new ways to treat notoriously difficult-to-cure fungal infections ...
Breaking Biology Technology:SME's Advanced Manufacturing Media Recognizes "30 Under 30" Future Leaders of Manufacturing 2SME's Advanced Manufacturing Media Recognizes "30 Under 30" Future Leaders of Manufacturing 3SME's Advanced Manufacturing Media Recognizes "30 Under 30" Future Leaders of Manufacturing 4SME's Advanced Manufacturing Media Recognizes "30 Under 30" Future Leaders of Manufacturing 5Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 2Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 4Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 5ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 2ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4
... 2011 Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced that ... the filing of the Marketing Authorization Application (MAA) for ... the treatment and prevention of bleeding in individuals with ... that it will begin its regulatory review process of ...
... Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO ) announced ... Jim Holmes, Lifeline,s CEO said "While our efforts ... have not been successful.  We now are considering alternatives should ... Lifeline is not reflected in the current lack of liquidity ...
... have developed polymers that fluoresce in the presence of bacteria, ... wound infection using ultra-violet light. When contained ... of fluorescence detected will alert clinicians to the severity of ... which bind to either gram negative or gram positive bacteria ...
Cached Biology Technology:Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B 2Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B 3Lifeline Biotechnologies and Depository Trust Company 2Sheffield scientists shine a light on the detection of bacterial infection 2
(Date:6/26/2015)... June 26, 2015 ATL Technology, LLC, a top ... specialties in single use solutions, headquartered in Springville, ... (a California corporation with locations in ... San Jose, Costa Rica ). This acquisition ... with ATL Technology,s existing facility in ...
(Date:6/25/2015)... PRINCETON, N.J. , June 25, 2015  TAKE ... awarded a patent by the United States Patent and ... Data Standardization". This process leverages TAKE Solutions, Clinical Accelerators ... by over 50% (when compared to standardization without the ... At the heart ...
(Date:6/24/2015)... SAN JOSE, Calif. , June 24, 2015 ... leading developer of human interface solutions, today announced ... fingerprint sensor to provide secure authentication for its ... Having recently reached more than 200 million shipments ... shipment with Sharp reinforces Synaptics, strength, scalability and ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... new study shows that high school athletes playing at higher ... phenomenon attributed to physiological changes in the brain causing it ... the first time any research has linked altitude to sports-related ... the Colorado School of Public Health and co-author of the ...
... Study of the Liver (EASL) today publishes their revised ... C virus infection (HCV) (1). The EASL guidelines, ... designed to help physicians and other healthcare providers optimise ... It is estimated that approximately 160 million individuals, ...
... the development of tumours in over one per cent of ... gene CUX1 has been broadly linked to cancer development. ... pathway is activated that increases tumour growth. Drugs that inhibit ... and are in development thus highlighting a potential new targeted ...
Cached Biology News:Study shows first link between altitude and concussion 2EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus 2EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus 3Gene promotes 1 in 100 of tumors 2
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
PlusOne Acrylamide PAGE, 1 kg. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Gel Casting Chemicals....
... RNA Quantitation Kit is one of ... the quantitation of RNA in solution. ... more sensitive than absorbance measurements. As ... detected with fluorescence microplate readers and ...
Biology Products: